ASX ANNOUNCEMENT

9 January 2024

Investor Update Presentation

BRISBANE, Anteris Technologies Ltd (ASX: AVR) is pleased to provide a copy of an Investor Update Presentation to be held today at the Annual J.P. Morgan Healthcare Conference.

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd (ASX: AVR) is a structural heart company committed to designing, developing, and commercialising innovative medical devices. Founded in Australia, with a significant presence in Minneapolis, USA (a MedTech hub), Anteris is science-driven, with an experienced team of multidisciplinary professionals delivering transformative solutions to structural heart disease patients.

The Company's lead product, DurAVR™, is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVR™ THV was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons. It is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue. This biomimetic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.

DurAVR™ THV is made using ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue has been used clinically for over 10 years and distributed for use in over 50,000 patients worldwide.

The ComASUR™ Delivery System was designed to provide controlled deployment and accurate placement of the DurAVR™ THV with balloon-expandable delivery, allowing precise alignment with the heart's native commissures to achieve optimal valve positioning.

Anteris Technologies is set to revolutionise the structural heart market by delivering clinically superior solutions for significant unmet clinical needs.

Authorisation and Additional information

This announcement was authorised by the Board of Directors.

For more information:

Investor Relations (US)
Malini Chatterjee, Ph.D.
Managing Director
Blueprint Life Science Group
+1 917 330 4269

Investor Relations
investors@anteristech.com
Anteris Technologies Ltd
+61 1300 550 310 | +61 7 3152 3200

Website	www.anteristech.com
Twitter	@AnterisTech
Facebook	www.facebook.com/AnterisTech
LinkedIn	https://www.linkedin.com/company/anteristech

ANTERIS

Anteris Team Presentation

January 2024



DISCLAIMER

Summary information

This presentation has been prepared by Anteris Technologies Ltd (the "Company"). It is a presentation of general background information in summary form about the Company's activities current at the date of this presentation. The information does not purport to be complete, comprehensive or to comprise all the information which a potential investor may require in order to determine whether to deal in the Company's securities, nor does it contain all the information which would be required in a disclosure document prepared in accordance with the Corporations Act 2001 (Cth) (the "Corporations Act"). It is to be read in conjunction with the Company's other announcements released to the Australian Securities Exchange ("ASX") (available at www.asx.com.au).

No offer, advice or recommendation

This presentation is for information purposes only and should not be read or understood as an offer, invitation, solicitation, inducement or recommendation to subscribe, buy or sell securities in the Company in any jurisdiction. This presentation will not form any part of any contract or commitment for the acquisition of the Company's securities. This presentation is not a prospectus or other offering document under Australian law or any law. It will not be lodged with the Australian Securities and Investments Commission ("ASIC").

Nothing contained in this presentation constitutes financial product, investment, legal, tax or other advice. It does not take into account the investment objectives, financial situation or needs of any particular investor. You should consider the appropriateness of the information in this presentation having regard to your own investment objectives, financial situation and needs and with your own professional advice, when deciding if an investment is appropriate.

Not for distribution or release in the United States

This presentation may not be distributed or released in the United States and may not be viewed by persons within the United States or transmitted to "U.S. persons" (within the meaning of Regulation S under the U.S. Securities Act of 1933 (the "Securities Act")), except to "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) ("QIBs"). This presentation and the information contained herein does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in any jurisdiction in which such offer would be illegal. The securities are being offered only to persons reasonably believed to be QIBs in accordance with Rule 144A under the Securities Act and to persons outside the United States in compliance with Regulation S. Any securities described in this presentation have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold, directly or indirectly, in the United States unless the securities have been registered under the Securities Act (which the Company has no obligation to do or to procure) or are offered or sold pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable securities laws of any state or other jurisdiction of the United States.

The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe such restrictions.

Forward-looking statements

This presentation contains forward looking statements Forward-looking statements can generally be identified by use of words such as "may", "should", "could", "foresee", "plan", "aim", "will", "expect", "intend", "project", "estimate", "anticipate", "believe", "forecast", "target", "outlook", "guidance" or "continue" or similar expressions. Forward looking statements include statements about the future financial or operating performance of the Company and its related bodies corporate, statements about the Company's current and future clinical studies, statements about the obtention and timing of regulatory approvals for the Company's products under development, statements about the Company's plans, strategies and objectives, including regarding the commercialization of its products, and statements about the industry and the markets in which the Company operates and statement about the effect of the offer described herein and proposed use of proceeds. Such statements represent the Company's current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant technical, business, economic, competitive, political and social risks, contingencies and uncertainties.

These forward-looking statements are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company and its related bodies corporate and affiliates (and each of their respective directors, securityholders, officers, employees, partners, agents, advisers and management), and could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements or any projections and assumptions on which those statements are based.

Forward-looking statements are provided as a general guide only and should not be relied on as an indication or guarantee of future performance.

DISCLAIMER CONT.

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intent or obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. All forward-looking statements made in this presentation are qualified by the foregoing cautionary statements. Investors are cautioned that forward-looking statements are not predictions or guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

Financial data

All currency amounts are in Australian Dollars ("$") unless otherwise stated.

Investors should be aware that financial data in this presentation include "non-IFRS financial information" under ASIC Regulatory Guide 230 "Disclosing non-IFRS financial information" published by ASIC and also "non-GAAP financial measures" within the meaning of Regulation G under the U.S. Securities Exchange Act of 1934, and are not recognised under Australian Accounting Standards ("AAS") and International Financial Reporting Standards ("IFRS"). The disclosure of non-GAAP financial measures in the manner included in this presentation may not be permissible in a registration statement under the Securities Act. The non-IFRS financial information/non-GAAP financial measures in this presentation may not have a standardised meaning prescribed by AAS or IFRS and may therefore not be comparable to similarly titled measures presented by other entities and should not be construed as an alternative to other financial measures determined in accordance with AAS or IFRS.

Although the Company believes this non-IFRS financial information/non-GAAP financial measures provides useful information to users in measuring the financial performance and condition of the Company, investors are cautioned not to place undue reliance on any non-IFRS financial information/non-GAAP financial measures included in this presentation.

The financial information in this presentation is presented in an abbreviated form insofar as it does not include all the disclosures required by the AAS and other mandatory professional reporting requirements applicable to general purpose financial reports prepared in accordance with the Corporations Act.

A number of figures, amounts, percentages estimates, calculations of value and other fractions used in this presentation are subject to the effect of rounding.

Past performance

Past performance is given for illustrative purposes only. It should not be relied on and is not indicative of future performance, including future security prices.

Market data

Certain market and industry data used in this presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither the Company nor its representatives or its advisers have independently verified any market data ("Market Data") or industry data provided by third parties or industry or general publications.

Market Data is provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. The Market Data may assume the success of the Company's business strategies, the success of which may not be realised within the period for which the Market Data has been prepared, or at all.

No guarantee, representation or warranty, express or implied, is made as to the accuracy, likelihood or achievement or reasonableness of any Market Data. Except as required by applicable laws, rules or regulations, none of the Issuer, its representatives or advisers intends to, or undertakes to, or assumes any obligation to, provide any additional information or revise the Market Data, whether as a result of a change in expectations or assumptions, new information, future events, results or circumstances.

ANTERIS

Anteris has taken a deliberate approach to solving a critical problem. By creating a new class of Aortic valve we have demonstrated superior results in US and European studies. Anteris with its unique and proven technology is on track to be market leader in a USD 10 bn space due to its superior clinical results.

OVERVIEW

The Aortic stenosis market is the largest in Medtech. The space has not had any new technology entrants since inception.

Anteris identified a clinical gap and designed its product with Physician input to close that gap. The clinical trial results are best in class as a result

Anteris took a calculated approach to a specific clinical problem (to achieve normal pre disease hemodynamics)

TAM	GROWTH	New technology entries since inception
USD 10-13 Billion (2028)	16% CAGR	0

MARKET SIZE

Anteris has combined 3 unique technologies (ADAPT®,DurAVR™, ComASUR™) To create the first new class of treatment for Aortic stenosis in 2 decades.

The DurAVR™ valve has demonstrated clinical superiority over the market leader in European and US studies (> 40%).

DurAVR™ is positioned to take market leadership (>65%) based on these results.

BY 2028

$USD 13BN

TAVR MARKET

(16% CAGR)

16%

TAVR MARKET

$USD 32K

Current TAVR ASP per unit

Key investment highlights

Anteris has developed and combined 3 distinct medical technologies to treat the fatal disease, Aortic Stenosis.

1. Anteris™ is competing in a forecast **US$10-13bn market by 2028** for the treatment of Aortic Stenosis
2. **Clinical studies** underway are **demonstrating superiority >30% to market leader.**
3. ADAPT® is the proprietary anti-calcification treatment platform technology on which our structural heart products are built. It is the **only anti-calcification treatment to demonstrate zero calcification in humans** over 10 years
4. ADAPT® has been distributed for use in over **55,000 patients globally** and is **FDA approved**
5. DurAVR™ is the **first new class of valve in 20 years** with **full IP protection. The new class (Biomimetic) results in clinically better outcomes.**
6. ComASUR™ is a **proprietary delivery system / catheter** that is used to place DurAVR™ in patients. The first delivery system designed from the ground up by high volume TAVR physicians.



COMPARE & CONTRAST

Anteris has created the first new class of TAVR in 2 decades. The product was created to deliberately fill a clinical and strategic gap in the market. The result is proven clinical superiority to the market leader.



Existing technologies did not advance with the increasing clinical knowledge of Aortic Stenosis over 20 years. This left a strategic and clinical gap in the market which required a new and novel design approach to deliver better clinical outcomes

Market overview | US$13bn+ market opportunity

The aortic stenosis patient population is under penetrated, with only ~15-20% of severe AS cases treated today. The TAVR market is currently around US$7bn+ and is expected to grow to ~US$10-13bn by 2028.

TAVR Aortic Stenosis + Valve-in-Valve market value[1]

(US$bn)



The world population continues to age rapidly and the incidence of aortic stenosis and severe aortic stenosis is growing with the population

Source: Management estimates. Notes: (1) 2020 Clarivate Market Data and Anteris inhouse Data.

Market overview | Understanding the issue

Anteris has created the first new valve design in over 20 years to treat Aortic Stenosis.

Overview of Aortic Stenosis ("AS")



- Aortic Stenosis is the condition when the aortic valve in the heart narrows
- This restricts blood flow and increases the burden on the heart to pump blood
- 1 in 8 people over 75 have Aortic Stenosis
- Severe Aortic Stenosis is fatal if left untreated in 50% of patients over 2 years

Source: Heartscope Specialist Group.

Treatment options for Aortic Stenosis



Surgical Aortic Valve Replacement ("SAVR")

- Generally includes an open heart surgery where an incision is made in the chest
- Temporary stopping of the heart (a heart-lung (bypass) machine takes over during the operation)



Transcatheter Aortic Valve Replacement ("TAVR")

- Replacement valve is delivered through blood vessels, most commonly through the vessels in the thigh
- Minimally invasive procedure (does not require open heart surgery)

The journey of Anteris becoming a structural heart company

ANTERIS TECHNOLOGIES

Evolution of Company and Product Focus

- **2008** — ADAPT® Tissue FIH
- **2014** — ADAPT® Tissue (CardioCel)
- **2017** — 3D Molded ADAPT® Tissue
- **2018** — pivot: Sale to LeMaitre pivoted the company to 100% focus on Structural Heart (starting with TAVR)
- **2019** — DurAVR™ Surgical FIH (Leuven, BE)
- **2020**
- **2021** — Today: DurAVR™ Transcatheter Heart Valve

Evolution of Medical Advisory Board

First MAB

MAB
Hands-on Lab at TVT



DurAVR™ A New Class of TAVR

Single-piece, native-shaped biomimetic design built to mimic the performance of a healthy aortic valve.



Caution: Investigational Device. Limited by Federal law to investigational use only.
Exclusively for clinical investigations.

Product overview | First-in-class biomimetic TAVR

Anteris has addressed unmet medical needs with a new class of products for the treatment of aortic stenosis. This first-in-class biomimetic technology can be used for new patients,(USD 10 BN) and replace existing valves in patients(USD 3 BN) (valve-in-valve ("ViV")).





ADAPT®

- Anti-calcification tissue technology
- Tissue processing
- Anteris' patented technology

DurAVR™ THV

- Novel biomimetic valve
  - Shaped to perform like a native aortic valve
- Single piece tissue
- Improved coronary access
- US patent protected design (11,648,107 and 11,622,853)

ComASUR™ Delivery System

- Provides controlled deployment and accurate alignment of the DurAVR™ THV valve with the position of the native aortic valve
- Patent for the sterilised packaging system

Product overview | Patent protected

Anteris has been issued patents for its ground breaking biomimetic design, which has changed the landscape.

To Promote the Progress of Science and Useful Arts

The Director

of the United States Patent and Trademark Office has received an application for a patent for a new and useful invention. The title and description of the invention are enclosed. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law.

Therefore, this United States

Patent

grants to the person(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America or importing the invention into the United States of America, and if the invention is a process, of the right to exclude others from using, offering for sale or selling throughout the United States of America, products made by that process, for the term set forth in 35 U.S.C. 154(a)(2) or (c)(1), subject to the payment of maintenance fees as provided by 35 U.S.C. 41(b). See the Maintenance Fee Notice on the inside of the cover.

Katherine Kelly Vidal

DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE



(12) **United States Patent**
Quill et al.

(10) **Patent No.: US 11,622,853 B1**
(45) **Date of Patent: Apr. 11, 2023**

(54) **PROSTHETIC HEART VALVES**

(71) Applicant: **Anteris Technologies Corporation**, Eagan, MN (US)

(72) Inventors: **Jason Quill**, Forest Lake, MN (US); **William Leon Neethling**, Booragoon (AU); **Christopher B. Brodeur**, Plymouth, MN (US); **Ramji Iyer**, Plymouth, MN (US); **Kaitlyn Roth**, Plymouth, MN (US)

(73) Assignee: **Anteris Technologies Corporation**, Eagan, MN (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **17/957,675**

(22) Filed: **Sep. 30, 2022**

(51) **Int. Cl.**
A61F 2/24 (2006.01)

(52) **U.S. Cl.**
CPC ***A61F 2/2418*** (2013.01); ***A61F 2/2412*** (2013.01); *A61F 2220/0075* (2013.01)

(58) **Field of Classification Search**
CPC A61F 2/2412; A61F 2/2415; A61F 2/2418
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,624,822	A	11/1986	Arru et al.
5,855,601	A	1/1999	Bessler et al.
6,491,511	B1	12/2002	Duran et al.
6,682,559	B2	1/2004	Myers et al.
7,025,780	B2	4/2006	Gabbay
7,087,079	B2	8/2006	Navia et al.
8,778,018	B2	7/2014	Iobbi
8,992,599	B2	3/2015	Thubrikar et al.
9,011,525	B2	4/2015	Claiborne, III et al.
9,095,430	B2	8/2015	Cunanan et al.
9,192,470	B2	11/2015	Cai et al.
9,205,172	B2	12/2015	Leonard Neethling et al.
9,259,313	B2	2/2016	Wheatley
9,301,833	B2	4/2016	Campbell et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN	203736349	7/2014
EP	2777618	9/2014

(Continued)

OTHER PUBLICATIONS

International Search Report and Written Opinion in International Appln. No. PCT/US2018/050669, dated Nov. 26, 2018, 10 pages.

(Continued)

Primary Examiner — Suba Ganesan
(74) *Attorney, Agent, or Firm* — Fish & Richardson P.C.

(57) **ABSTRACT**

This document provides devices and methods for the treatment of heart conditions. For example, this document provides prosthetic heart valves and transcatheter heart valve replacement methods. The prosthetic heart valves can be configured into a low-profile configuration for containment within a small diameter delivery sheath. The prosthetic heart valves include can include a valve member attached to a stent frame. In some embodiments, the valve member is a molded biomaterial with a novel shape and resulting performance characteristics. Localized protective covering members can be attached to the stent frame to prevent the valve member from contacting the stent frame as the valve member cycles between its open and closed configurations.

20 Claims, 6 Drawing Sheets



FIG. 1



FIG. 2

FIG. 3

US and European studies

- 50 patients
- 6 Valve in Valve
- Primary end points met
- Clinical superiority demonstrated as measured by the defining disease parameters of EOA, MPG
- Significant improvement in clinical status
- Significant improvement in QOL
- Significant improvement in exercise tolerance

Excellent Safety Profile

- No death
- No stroke
- No permanent pacemaker
- No major bleeding/vascular complications
- No re-interventions or re-operation

DurAVR™ delivers excellent haemodynamic results

Consistent Results through 1 Year
First-in-Human



Continued Haemodynamic Excellence
US Early Feasibility Study



** To date*
EFS Data Echo Core Lab Analysis

Paradigm Shifting 30-day EFS Hemodynamic Results*

Mean Annulus size: 22.1 mm

EOA
(Effective Orifice Area)

2.18

cm^2

MPG
(Mean Pressure Gradient)

7.8

mmHg

DVI
(Doppler Velocity Index)

0.63

No PVL reported at 30-day follow-up
(30-day Follow-Up, n=14)

*Echo Core Lab Analysis

Easy to Deliver, Precise Placement and Great PVL Results



100%
successful delivery



93% no/trace PVL
7% mild PVL

Clinical data | Cohort 1, 2 and 3

26 patients are now implanted with DurAVR™, with excellent results that have been maintained over 1 year.

Baseline characteristics	Cohort 1 and 2	Cohort 3
Number of patients	n = 13	n = 7
Age (years)	73.92 ± 6.4	74.86 ± 4.60
Gender (female)	77%	86%
STS Prom (%)	2.34 ± 1.07	2.07 ± 0.47
Area-derived annulus diameter (mm)	22.95 ± 1.09	22.33 ± 1.51
NYHA Class (II, III)	85%, 15%	71%, 29%
Implant timeframe	Nov-2021 and May-2022	April 2023

Cohort 1 and 2 results summary

Effective Orifice Area ("EOA")
(



Mean Pressure Gradient ("MPG")
(

- Mild AS: 15-25
- Moderate AS: 25-40
- Severe AS: 40+



Kansas City Cardiomyopathy Questionnaire ("KCCQ") overall summary score

- Quantifies clinical symptoms in heart failure (symptoms, physical function, quality of life and social limitations)
  - 0 to 24 - very poor to poor
  - 25 to 49 - poor to fair
  - 50 to 74 - fair to good
  - 75 to 100 - good to excellent



Average distance walked (mt)

- Indicator of exercise capacity



Notes: (§) One subject performed the baseline and 30-day 6MWT with the support of an assistive device and was unable to complete the assessment at 6-month and 1-year follow-up due to hip replacement.

DurAVR™ is the first AVR shown to restore normal aortic flow

Normal Valve Flow vs DurAVR™: *No Significant Difference in Flow (p=0.45)*

Healthy Aortic Valve





Flow Displacement (FD) = 12%
Flow Reversal Ratio (FRR) = 0%

Post DurAVR™ THV





Flow Displacement (FD) = 14%
Flow Reversal Ratio (FRR) = 4%

Impaired Aortic Flow

Severe AS
FD = 46%
FRR = 23%



Edwards' Sapien 3
FD = 48%
FRR = 35%



Medtronic's Evolut R
FD = 25%
FRR = 4%



Edward's CEP Magna Ease
FD = 27%
FRR = 30%



Severe AS

Normal Valve Flow vs TAVR: *p<0.05*

Normal Valve Flow vs SAVR: *p<0.001*

DurAVR™ is a first in class Biomimetic valve that outperforms the market leader

Biomimetic performance is needed for a restorative effect. Patients are increasingly younger and need restorative therapy to return to a pre-disease quality and length of life.

Bioprosthetic Valve

*Competitor valves **look like nature** but have turbulent blood flow performance*

Sapien 3

Evolut



48% Flow Displacement
35% Flow Reversal Ratio



25% Flow Displacement
4% Flow Reversal Ratio

Turbulent flow treats symptoms of severe AS disease

Biomimetic Valve

*DurAVR™ **works like nature** with natural blood flow performance*



Healthy valve performance comparator



12% Flow Displacement
0% Flow Reversal Ratio



DurAVR™



14% Flow Displacement
4% Flow Reversal Ratio

Native like performance addresses underlying affects of AS disease

DurAVR™ A New Class of TAVR

DurAVR™ biomimetic valve provided outstanding hemodynamic performance in independent core lab adjudicated data

Delivery System was intuitive and easy to use, even with first time users

DurAVR™ EFS results demonstrated excellent safety profile

30-day EFS result presented at PCR London Valve Late Breaking Clinical Trials session



ANTERIS

THANK YOU